DSS, Inc. - DSS STOCK NEWS

Document Security Systems, Inc. (NYSE American: DSS) announced the closing of a public offering generating $50.025 million in gross proceeds. The offering consisted of 29 million shares at $1.50 per share, with an additional 4.35 million shares sold via the underwriters' over-allotment option. These funds will support growth in new business lines, acquisitions, and general corporate needs. The offering was executed under a shelf registration statement effective as of June 7, 2021.

Document Security Systems (DSS) announced that its subsidiary, Impact BioMedical, received a patent from the USPTO for its 3FDB, a revolutionary mosquito repellent technology. This formulation enhances existing repellents like DEET by targeting multiple mosquito receptors to provide superior efficacy. The team discovered its active ingredients in the ghost orchid, which naturally repels mosquitoes. With the mosquito repellent market projected to reach $1.2 billion by 2025, DSS aims to leverage this innovation to save lives and address global health challenges related to mosquito-borne diseases.

Document Security Systems, Inc. (DSS) has priced a public offering of 29 million shares at $1.50 per share, aiming for gross proceeds of approximately $43.5 million. The funds will support the company's expansion into new business lines and cover working capital needs. Additionally, underwriters have an option to purchase up to 15% more shares, potentially raising total proceeds to $50 million. The offering is filed under a shelf registration statement effective June 7, 2021.

DSS acquires 24.9% of Sentinel Brokers Company, Inc. as part of its strategic expansion in the financial services sector. The agreement includes an option to buy an additional 50.1%, aimed at enhancing the ecosystem around DSS Securities. Established in 1996, Sentinel, a FINRA-registered broker-dealer, specializes in institutional trading of bonds and preferred stocks. DSS aims to leverage this acquisition to accelerate its digital securities business and capitalize on growth opportunities in the industry.

Document Security Systems (DSS) has launched a new subsidiary, DSS PureAir, focusing on air purification technology. Recent studies from the University of Florida show that products from Puradigm, a company DSS invested in, can effectively neutralize SARS-CoV-2 on surfaces, with a 97.7% decrease in viral infectivity after four hours. The air purifier market, valued at $10.7 billion in 2020, is projected to grow by 10% annually until 2028. DSS PureAir aims to capitalize on this growth with advanced purification solutions.

Document Security Systems (DSS) announced that Proof Authentication Corporation has acquired 100% of DSS Digital, Inc., enhancing shareholder value by focusing on higher-return opportunities. The agreement allows DSS to license its anti-counterfeit technology to key customers while investing in growth areas like healthcare and renewable energy. The deal includes upfront cash and potential earn-out payments based on revenue targets. CEO Frank D. Heuszel highlighted the shift towards innovative solutions, indicating a strategic move to revitalize DSS's operations and drive market value.

Document Security Systems (DSS) announced that its subsidiary, Premier Packaging Corporation, will relocate to a new 105,000 sq. ft. facility in Henrietta, NY, to accommodate rising customer demand. The move, expected by year-end 2021, is backed by up to $700,000 in state tax credits contingent on job creation. Premier aims to boost staffing by over 50% and enhance operational capacity through new investments. DSS's management emphasizes this transition as vital for Premier's growth and market leadership, aided by local government support.

DSS announced its subsidiary, DSS Biomedical, completed an equity investment in Vivacitas Oncology, a clinical-stage company specializing in difficult-to-treat cancers. This investment highlights DSS's commitment to addressing healthcare needs and provides Vivacitas with significant growth potential. Additionally, DSS Biomedical acquired Impact Oncology, whose principal assets include equity in Vivacitas. The agreements allow DSS to appoint two members to Vivacitas's board, further strengthening their partnership.

DSS has launched Alset Solar, Inc., a subsidiary aimed at developing utility-scale solar farms. This initiative targets underutilized and contaminated lands to generate clean energy, thereby addressing community concerns about land use. Melissa Sims, Director of Alset Solar, emphasizes the potential of solar energy to combat climate change and enhance energy access. Alset Solar will focus on key markets in the US sunbelt, working closely with communities to repurpose blighted lands. This move aligns with the increasing demand for renewable energy.